Wenjia Ai

Dr. Wenjia Ai

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
JGJia Guo
Jia Guo
QZQing Zhang
Qing Zhang
ZLZhidong Li
Zhidong Li
MQMin Qin
Min Qin
JSJinyun Shi
Jinyun Shi
BXBaohui Xu
Baohui Xu
Abdominal aortic aneurysm (AAA) is a chronic aortic disease that lacks effective pharmacological therapies. This study was performed to determine the influence of treatment with the gasdermin D inhibitor necrosulfonamide on experimental AAAs. AAAs were induced in male apolipoprotein E-deficient mice by subcutaneous angiotensin II infusion (1000 ng/kg body weight/min), with daily administration of necrosulfonamide (5 mg/kg body weight) or vehicle starting 3 days prior to angiotensin II infusion for 30 days. Necrosulfonamide treatment remarkably suppressed AAA enlargement, as indicated by reduced suprarenal maximal external diameter and surface area, and lowered the incidence and reduced the severity of experimental AAAs. Histologically, necrosulfonamide treatment attenuated medial elastin breaks, smooth muscle cell depletion, and aortic wall collagen deposition. Macrophages, CD4+ T cells, CD8+ T cells, and neovessels were reduced in the aneurysmal aortas of necrosulfonamide- as compared to vehicle-treated angiotensin II-infused mice. Atherosclerosis and intimal macrophages were also substantially reduced in suprarenal aortas from angiotensin II-infused mice following necrosulfonamide treatment. Additionally, the levels of serum interleukin-1β and interleukin-18 were significantly lower in necrosulfonamide- than in vehicle-treated mice without affecting body weight gain, lipid levels, or blood pressure. Our findings indicate that necrosulfonamide reduced experimental AAAs by preserving aortic structural integrity as well as reducing mural leukocyte accumulation, neovessel formation, and systemic levels of interleukin-1β and interleukin-18. Thus, pharmacologically inhibiting gasdermin D activity may lead to the establishment of nonsurgical therapies for clinical AAA disease.

1 January 2025 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
WAWenjia Ai
Wenjia Ai
FLFangfei Li
Fangfei Li
QYQilin Yang
Qilin Yang
JQJingluo Qiu
Jingluo Qiu
AZAiqiang Zhou
Aiqiang Zhou
ZZZhihui Zhang
Zhihui Zhang
Background: Identifying high‐risk patients with acute pulmonary embolism is vital for improving disease prognosis. However, current guidelines and research on risk factors are insufficient to meet clinical needs. This study was aimed at exploring novel risk factors to predict in‐hospital mortality. Methods: We utilized a patient cohort from the Medical Information Mart for Intensive Care Version IV (MIMIC‐IV) database as training cohort. Major analyses included screening risk factors for in‐hospital mortality, correlation analysis via smooth curve fitting, multivariate Cox regression, and subgroup analysis. The findings were further validated with our own institute patient cohort. Results: Among 1463 adult patients with acute pulmonary embolism in the MIMIC‐IV database, the overall in‐hospital mortality rate was 17.8%. A nonlinear correlation was observed between urine output and in‐hospital mortality. A urine discharge less than 0.85 mL/kg/h was used as the threshold and was negatively associated with the risk for in‐hospital death. Compared to patients with urine value < 0.5 mL/kg/h, the risk for in‐hospital mortality reduced by 36% and 48% in patients with urine values of 0.5–0.85 mL/kg/h and > 0.85 mL/kg/h, with the hazard ratios of 0.64 (0.47, 0.87) and 0.52 (0.38, 0.72), respectively. This association remained significant in the subgroup analysis after adjusting for age, gender, hypotension, and low oxygen saturation. Our validation patient cohort ( n = 151) further confirmed the strong association of the urine value with in‐hospital mortality and consistent cutoff value. Conclusion: Our study revealed a negative association of urine output with in‐hospital mortality in acute pulmonary embolism patients, with the optimal urine output being significantly higher than the value of other critical illnesses.

8 November 2024 in Journal of Vascular Surgery: Venous and Lymphatic Disorders
Verified
Journal Article
Open access
JQJingluo Qiu
Jingluo Qiu
WAWenjia Ai
Wenjia Ai
WGWenduo Gu
Wenduo Gu
SLShaomang Lin
Shaomang Lin
JXJianbin Xiao
Jianbin Xiao
ZZZhihui Zhang
Zhihui Zhang
Patients with mixed-type lower extremity deep vein thrombosis (DVT) have a higher incidence of post-thrombotic syndrome (PTS) after endovascular treatment (EVT). This study aimed to identify risk factors associated with PTS in these patients after EVT. This retrospective study included patients diagnosed with acute mixed-type lower extremity DVT who underwent EVT between January 2020 and December 2022. Patient assessments were conducted using ultrasound examination and the Villalta scale. Baseline characteristics, management details, and follow-up findings were compared between patients who developed PTS and those who did not at 6 months after EVT. Cox regression and nomogram analyses were performed to identify risk factors associated with the development of PTS. The study enrolled 118 patients, of which 103 completed the follow-up. Among them, 24.3% developed post-thrombotic syndrome (PTS) within 6 months. Significant differences between the PTS and non-PTS groups were found concerning residual thrombosis in the popliteal, common femoral, and femoral veins. Multivariate Cox regression analysis indicated that residual popliteal vein thrombosis (RPVT) (hazard ratio [HR], 4.93; 95% confidence interval [CI], 1.61-15.11) and preoperative iliac vein stenosis (HR, 3.21; 95% CI, 1.11-9.33) were significant risk factors for PTS. Additionally, subgroup analysis for preoperative iliac vein stenosis and sensitivity analysis confirmed that RPVT remained a risk factor for PTS (HR, 4.48; 95% CI, 1.27-15.84). Our study demonstrated a positive association between RPVT and PTS in patients with extensive mixed-type lower extremity DVT after EVT. These findings suggest that intensive monitoring and aggressive therapeutic interventions may be required for patients with RPVT to decrease the risk of PTS.

Verified
Journal Article
Open access
PDF file
JXJianbin Xiao
Jianbin Xiao
TQTao Qiu
Tao Qiu
HWHong Wang
Hong Wang
HZHongji Zha
Hongji Zha
JCJiayue Chen
Jiayue Chen
ZZZhihui Zhang
Zhihui Zhang
Abdominal aortic aneurysm (AAA) enlargement is a major risk factor for aneurysm rupture and the development of abdominal aneurysm dissection (AAD). However, reliable serum biomarkers for predicting AAD occurrence remain lacking. This study was designed to identify circulating serum markers capable of predicting AAA progression and AAD formation. Patients diagnosed with AAA or AAD at our institution between 2020 and 2025 were enrolled and corresponding clinical characteristics were analyzed. Peripheral blood levels of arachidonic acid (AA) and 12–HETE were measured using ELISA, and Alox12 mRNA expression was determined by quantitative real-time polymerase chain reaction (qRT-PCR). Candidate serum biomarkers associated with AAA enlargement and AAD development were investigated using a multi-modal approach integrating computed tomography (CT) images, serum metabolic profiles, and aneurysm wall tissue analyses. A total of 52 AAA patients and 42 AAA patients were included in the analysis. Elevated serum 12–HETE and TG levels were significantly associated with AAA enlargement and the occurrence of AAD, whereas AA levels showed no significant difference between groups. Dysregulated AA/12–HETE metabolism is an independent risk factor for aneurysmal enlargement in AAA and AAD, while 12–HETE and TG help to discriminate AAD from AAA.

Verified
Journal Article
Open access
PDF file
YLYankui Li
Yankui Li
RGRachel C. Gunderson
Rachel C. Gunderson
ZXZeyu Xu
Zeyu Xu
WAWenjia Ai
Wenjia Ai
FSFanru Shen
Fanru Shen
SMSara A Michie
Sara A Michie
Type 1 diabetes (T1D) is an autoimmune disease that is caused by autoreactive T cell-mediated destruction of insulin-producing β cells in the pancreatic islets. Although naive autoreactive T cells are initially primed by islet antigens in pancreas-draining lymph nodes (pan-LNs), the adhesion molecules that recruit T cells into pan-LNs are unknown. We show that high endothelial venules in pan-LNs of young nonobese diabetic mice have a unique adhesion molecule profile that includes strong expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Anti-MAdCAM-1 antibody blocked more than 80% of the migration of naive autoreactive CD4+ T cells from blood vessels into pan-LNs. Transient blockade of MAdCAM-1 in young nonobese diabetic mice led to increased numbers of autoreactive regulatory CD4+ T cells in pan-LNs and pancreas and to long-lasting protection from T1D. These results indicate the importance of MAdCAM-1 in the development of T1D and suggest MAdCAM-1 as a potential therapeutic target for treating T1D.